NCT03811652 - A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

December 10, 2019

Study Completion Date

December 10, 2019

Conditions

Non Small Cell Lung Cancer Squamous (NSCLC-Sq)Head and Neck Squamous Cell Carcinoma (HNSCC)Small Cell Lung Cancer (SCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG

MEDI7247

Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Trial Locations (3)

28078

Research Site, Huntersville

37203

Research Site, Nashville

M5G 2M9

Research Site, Toronto